A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza
Public ClinicalTrials.gov record NCT01231620. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III International, Randomized, Double-blind, Double-dummy Study to Evaluate the Efficacy and Safety of 300 mg or 600 mg of Intravenous Zanamivir Twice Daily Compared to 75 mg of Oral Oseltamivir Twice Daily in the Treatment of Hospitalized Adults and Adolescents With Influenza
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to test the safety and efficacy of zanamivir given intravenously and how well it works at two different doses in hospitalized adolescents and adults with flu. Zanamivir will be compared with oseltamivir, which is used for treating flu.
Study identification
- NCT ID
- NCT01231620
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 626 participants
Conditions and interventions
Conditions
Interventions
- Zanamivir Drug
- Placebo to match zanamivir Drug
- Oseltamivir Drug
- Placebo to match oseltamivir Drug
Drug
Eligibility (public fields only)
- Age range
- 16 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 15, 2011 (Actual)
- Primary completion
- Mar 18, 2015 (Actual)
- Completion
- Mar 18, 2015 (Actual)
- Last update posted
- Oct 15, 2018
2011 – 2015
United States locations
- U.S. sites
- 40
- U.S. states
- 25
- U.S. cities
- 40
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Birmingham | Alabama | 35249 | — |
| GSK Investigational Site | Phoenix | Arizona | 85023 | — |
| GSK Investigational Site | Chula Vista | California | 91911 | — |
| GSK Investigational Site | Escondido | California | 92025 | — |
| GSK Investigational Site | Fullerton | California | 92835 | — |
| GSK Investigational Site | La Jolla | California | 92037 | — |
| GSK Investigational Site | La Mesa | California | 91942 | — |
| GSK Investigational Site | Oceanside | California | 92056 | — |
| GSK Investigational Site | Aurora | Colorado | 80045 | — |
| GSK Investigational Site | Stamford | Connecticut | 06902 | — |
| GSK Investigational Site | Orlando | Florida | 32806 | — |
| GSK Investigational Site | Sarasota | Florida | 34239 | — |
| GSK Investigational Site | Sunrise | Florida | 33323 | — |
| GSK Investigational Site | Atlanta | Georgia | 30342 | — |
| GSK Investigational Site | Augusta | Georgia | 30912 | — |
| GSK Investigational Site | Idaho Falls | Idaho | 83404 | — |
| GSK Investigational Site | Chicago | Illinois | 60611 | — |
| GSK Investigational Site | Oak Park | Illinois | 60302 | — |
| GSK Investigational Site | Peoria | Illinois | 61637 | — |
| GSK Investigational Site | Council Bluffs | Iowa | 51503 | — |
| GSK Investigational Site | Topeka | Kansas | 66604 | — |
| GSK Investigational Site | Louisville | Kentucky | 40241 | — |
| GSK Investigational Site | Boston | Massachusetts | 02115 | — |
| GSK Investigational Site | Royal Oak | Michigan | 48073 | — |
| GSK Investigational Site | Troy | Michigan | 48085 | — |
| GSK Investigational Site | St Louis | Missouri | 63110-1093 | — |
| GSK Investigational Site | Missoula | Montana | 59802 | — |
| GSK Investigational Site | Las Vegas | Nevada | 89109 | — |
| GSK Investigational Site | Valhalla | New York | 10595 | — |
| GSK Investigational Site | Asheville | North Carolina | 28801 | — |
| GSK Investigational Site | Chapel Hill | North Carolina | 27599-7215 | — |
| GSK Investigational Site | Bismarck | North Dakota | 58504 | — |
| GSK Investigational Site | Cleveland | Ohio | 44195 | — |
| GSK Investigational Site | Columbus | Ohio | 43215 | — |
| GSK Investigational Site | Toledo | Ohio | 43608 | — |
| GSK Investigational Site | Bethlehem | Pennsylvania | 18105 | — |
| GSK Investigational Site | Philadelphia | Pennsylvania | 19107 | — |
| GSK Investigational Site | Houston | Texas | 77030 | — |
| GSK Investigational Site | Roanoke | Virginia | 24013 | — |
| GSK Investigational Site | Marshfield | Wisconsin | 54449 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 130 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01231620, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 15, 2018 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01231620 live on ClinicalTrials.gov.